In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.
In this in-depth conversation, they discuss the challenges of expanding Dexcom’s global footprint, the company’s reimbursement strategy, and the evolving role of regulators in fostering innovation.
Key Takeaways
While countries like France offer full reimbursement for CGM users, many healthcare systems still lag. Dexcom is working with policymakers, clinicians, and advocacy groups to expand coverage globally.
Continuous glucose monitoring (CGM) technology has transformed diabetes management, enabling real-time tracking of glucose levels and empowering individuals to make informed health decisions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
J&J’s global head of MedTech Digital envisions AI-powered connected operating suites within a decade. In an interview with Medtech Insight, Shan Jegatheeswaran discusses how J&J, together with partners like NVIDIA and AWS, is laying the foundation for open platforms for standardized surgeries.
IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla said.
A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.
NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.
For the third quarter of 2025, GE HealthCare projects year-over-year organic revenue growth in the range of 2%-3%. However, adjusted EPS is expected to decline in the high single digits year-over-year, reflecting the ongoing effect of tariff costs.
Healthtechs are reflecting on the resignation of Sam Roberts as chief executive of NICE and how medtech assessment program changes underway at the England and Wales HTA body might be impacted.
A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.
